Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

38.86 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
2 Exceptional Dividend Stocks Near 52-Week Lows You Could Regret Not Buying on the Dips ↗
Via The Motley Fool
News headline image
3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer ↗
Via The Motley Fool
News headline image
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Insights Ahead: Royalty Pharma's Quarterly Earnings ↗
 
Via Benzinga
News headline image
Peering Into Royalty Pharma's Recent Short Interest ↗
 
Via Benzinga
News headline image
3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade ↗
Via The Motley Fool
News headline image
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields ↗
 
Via Benzinga
News headline image
Royalty Pharma Reports Third Quarter 2024 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo
From Royalty Pharma plc
Via GlobeNewswire
News headline image
3 Dividend Growth Stocks to Buy Now for a Lifetime of Passive Income ↗
Buy these stocks now, and the yield on your original investment could reach a double-digit percentage long before you retire. 
Via The Motley Fool
News headline image
Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Declares Fourth Quarter 2024 Dividend
From Royalty Pharma plc
Via GlobeNewswire
News headline image
2 No-Brainer Dividend Stocks to Buy With $100 in October ↗
With their high yields and strong underlying businesses, these stocks are hard to pass up. 
Via The Motley Fool
News headline image
2 High-Yield Dividend Stocks Near 52-Week Lows: Are They Buys Now? ↗
These dividend-paying stocks offer hard-to-find high yields, but that doesn't necessarily make them good stocks to buy now. 
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade ↗
Now could be a great time to scoop up three stocks trading way below their previous peaks. 
Via The Motley Fool
News headline image
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100 ↗
These dividend payers could more than double their payouts in the decade ahead. 
Via The Motley Fool
News headline image
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut ↗
Ascendis Pharma reported lower-than-expected Q2 2024 sales of $38.76 million, missing the consensus estimate of $92.7 million due to a significant adjustment to prior sales estimates. The company... 
Via Benzinga
News headline image
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes 
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation' ↗
Jim Cramer discusses Snowflake, Royalty Pharma, Core Scientific and Ally Financial on "Mad Money Lightning Round." 
Via Benzinga
News headline image
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q2 2024 ↗
RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Royalty Pharma Reports Second Quarter 2024 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Declares Third Quarter 2024 Dividend
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal? ↗
CEO Robert Blum says there are key components to the funding arrangement with Royalty Pharma that investors are missing. 
Via Investor's Business Daily
News headline image
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024 ↗
Selecting strong buy biotech stocks isn’t easy when most of them don’t make money. Here are three possibilities to meet this challenge. 
Via InvestorPlace
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.